Navigation Links
Early stage, HER2-positive breast cancer patients at increased risk of recurrence
Date:12/12/2008

Angulo continued.

Current guidelines call for no additional therapy after surgery and radiation if tumors are less than five millimeters and Herceptin-based adjuvant therapy should be discussed with patients if the tumors are from six to 10 millimeters, Gonzalez-Angulo explained.

According to Gonzalez-Angulo, the number of patients with HER2 positive tumors smaller than one centimeter continues to increase as breast cancer surveillance and early detection become increasingly sophisticated.

"Before now, there's been no data regarding how to treat these women because they were excluded from all the definitive trials confirming Herceptin's benefit. This data strongly suggests that we need to rethink how we treat early-stage breast cancer patients with HER2 positive tumors and likely offer anti-HER2 therapy in the adjuvant setting."

For the retrospective study, Gonzalez-Angulo, Ranjay Rakkhit, M.D., a fellow in M. D. Anderson's Department of Hematology and Oncology and the study's first author, and their colleagues used M. D. Anderson's Breast Cancer Research Database to analyze 965 patients treated between 1990 and 2002. All of the patients' tumors were smaller than one centimeter; patients whose receptor status could not be analyzed and/or had received adjuvant chemotherapy or Herceptin at any time were excluded. The median age of the women at diagnosis was 57 years. To validate the findings, a second cohort of 350 patients from European institutions was also analyzed.

Of the M. D. Anderson patient population, more than 10 percent, or 98 patients, had HER2 positive tumors. In addition, 77 percent were hormone-receptor positive and 13 percent were triple receptor-negative.

In those analyzed with HER2 positive tumors, the five-year, recurrence-free survival was 77.1 percent; in contrast, HER2 negative patients' recurrence-free survival was 93.7 percent. Five-year distant recurrence-free survival was 86.4 percent in
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Light shines for potential early cancer diagnosis technique
2. U.S. Department of Education Funded Study Demonstrates, WordWorld, a PBS KIDS(R) Television Series Works as Critical Early Literacy Tool
3. Tarpon Fund Posts Strong Early Results : Innovative Fund From Islamorada Investment Management Gains 18.5% in November
4. Obesity among states low-income teens nearly triple that of more affluent peers
5. New partnership to foster healthier food habits in early childhood
6. Houston Mother Who Nearly Lost Her Daughter to Influenza Joins American Lung Associations Faces of Influenza Campaign to Promote Annual Vaccination
7. Vitamin B1 could reverse early-stage kidney disease in diabetes patients
8. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
9. Siskin Center for Child and Family Research to Focus on Early Childhood Development and Special Education
10. Folate in Early Pregnancy May Boost Wheezing in Baby
11. JCI online early table of contents: Dec. 1, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Early stage, HER2-positive breast cancer patients at increased risk of recurrence
Early stage, HER2-positive breast cancer patients at increased risk of recurrence
Breaking Medicine Technology:Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Vivakor Announces New Acquisition Strategy 2Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 1YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 3YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 4YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 5YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 6U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 1U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 2U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 3New Hampshire Rx Card Launching Statewide 5239 1New Hampshire Rx Card Launching Statewide 5239 2